Financial Performance - Standalone (Q1 FY27)
Income:
- Revenue from operations: ₹422.43 crore (Q1 FY26: ₹346.54 crore)
- Other income: ₹3.15 crore (Q1 FY26: ₹2.02 crore)
- Total income: ₹425.58 crore (Q1 FY26: ₹348.56 crore)
Expenses:
- Cost of materials consumed: ₹32.65 crore
- Purchases of Stock-in-trade: ₹57.20 crore
- Changes in inventories: (₹12.33) crore
- Employee benefits expense: ₹122.09 crore
- Finance costs: ₹2.69 crore
- Depreciation and amortization: ₹13.24 crore
- Other expenses: ₹129.69 crore
- Total expenses: ₹345.23 crore
Profitability:
- Profit before exceptional item and tax: ₹80.35 crore (Q1 FY26: ₹60.89 crore)
- Tax expense: ₹20.25 crore (Current tax: ₹18.38 crore, Deferred tax: ₹1.87 crore)
- Net Profit after tax: ₹60.10 crore (Q1 FY26: ₹46.40 crore)
- Other comprehensive loss: (₹0.30) crore
- Total comprehensive income: ₹59.80 crore
Per Share Data:
- Basic EPS: ₹9.83 (Q1 FY26: ₹7.59)
- Diluted EPS: ₹9.83 (Q1 FY26: ₹7.59)
- Paid-up equity share capital: ₹61.16 crore (face value ₹10/-)
Financial Performance - Consolidated (Q1 FY27)
Income:
- Revenue from operations: ₹422.43 crore
- Other income: ₹3.15 crore
- Total income: ₹425.58 crore
Profitability:
- Profit before share of profit of associate, exceptional item and tax: ₹80.35 crore
- Share of profit of associate: ₹0.01 crore
- Profit before tax: ₹80.36 crore
- Tax expense: ₹20.25 crore
- Net Profit after tax: ₹60.11 crore (attributable to owners)
- Total comprehensive income: ₹59.81 crore (attributable to owners)
Per Share Data:
- Basic EPS: ₹9.83
- Diluted EPS: ₹9.83
Exceptional Item
The financial results for year ended March 31, 2026 include an exceptional item of ₹19.10 crore (post tax ₹14.29 crore) representing the statutory impact of new Labour Codes notified by Government of India on November 21, 2025. This comprises:
- Gratuity impact: ₹13.60 crore
- Long-term compensated absences: ₹5.50 crore
The impact arises primarily due to change in wage definition under the new Labour Codes.
Operational Highlights from Press Release
- Revenue growth of 21.9% YoY for Q1 FY27
- PAT growth of 30.1% YoY for Q1 FY27
- PAT margins at 14.2% (increase of 90 bps YoY)
- EBITDA: ₹93.1 crore (33.5% YoY growth)
- EBITDA margin: 22.0% (190 bps improvement)
- Market rank improved to 26th position in Indian Pharmaceutical Market (from 29th)
- 5th rank in Gynaecology therapy segment
- Outperformed market by 1.9 times as per MAT June'26
- Fastest growing company among top 30 companies in IPM for last 6 consecutive months
Significant Events
- Inauguration and commercialization of EU-GMP approved Female Hormone Manufacturing Facility in Ahmedabad on June 30, 2026
- Initiated integration of acquired brand Wokadine from supply and distribution perspective
Entity Information
- Consolidated results include associate: La Chandra Pharmalab Private Limited
- Share of profit from associate: ₹0.01 crore for Q1 FY27
- Company has only one reportable business segment: Pharmaceuticals
Historical Context
- Company completed IPO on December 15, 2025 through offer for sale of 61,74,051 equity shares
- Issue price: ₹1,008 per share (employees), ₹1,062 per share (others)
- IPO expenses entirely allocated to selling shareholders